NASDAQ$BLTE
Belite Bio Inc · Q4 2026 earnings
Q4 2026 earnings · · Before market open · Investor relations
Briefing
BLTE Q4 2026 — extraction skipped
Belite Bio Inc filed Form 6-K (accession 0001104659-26-037376) for Q4 2026, but headline financial numerics could not be extracted automatically: cached document missing (fetch error or PDF). The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.
- Form 6-K filed; press release body not parseable here.
- Reason: cached document missing (fetch error or PDF).
- Numerics rely on the Financial Datasets fallback.
Headline financials
Revenue & EPS history
Belite Bio · Revenue · Quarterly
$0
Forward guidance
The Company remains on track to submit an NDA for tinlarebant to the FDA in Q2 2026 and continue advancing its Phase 2/3 and Phase 3 trials, supported by strengthened capital resources.
Tailwinds
- On track to submit NDA in Q2 2026.
- Completed enrollment in DRAGON II trial.
- PHOENIX Phase 3 trial fully enrolled.
- Completed 402000000 public offering to support commercialization.
- Strong liquidity position with substantial cash and investments.
Headwinds
- Increased R&D expenses due to clinical trial activities.
- Higher G&A expenses driven by share-based compensation.
- Net loss widened year-over-year.
- No product revenue generated.
- Continued dependence on successful regulatory approval.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2026
+0.3%
Avg return
Earnings day
+4.6%
Avg return
5 days after
+3.1%
Avg return
30 days after
31%
4 / 13 earnings
Positive
+36.6%
Q2 2022
Best reaction
-15.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.5% | — | — | |
| Q1 2025 | -3.4% | +3.9% | +0.2% | |
| Q4 2024 | +0.5% | -0.2% | -15.1% | |
| Q3 2024 | +4.6% | +5.3% | -19.4% | |
| Q2 2024 | -1.4% | +1.3% | -2.1% | |
| Q1 2024 | -0.1% | +6.9% | +18.8% | |
| Q4 2023 | -15.2% | -16.5% | -13.6% | |
| Q3 2023 | -3.7% | -5.4% | +12.3% | |
| Q2 2023 | +2.3% | +4.2% | +39.9% | |
| Q4 2022 | -3.4% | -1.2% | -1.9% | |
| Q4 2020 | -3.4% | -1.2% | -1.9% | |
| Q4 2021 | -3.4% | -1.2% | -1.9% | |
| Q2 2022 | +36.6% | +59.4% | +21.7% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro